These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24557012)

  • 1. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
    Zhang L; Ren X; Cheng Y; Liu X; Allen JE; Zhang Y; Yuan Y; Huang SY; Yang W; Berg A; Webb BS; Connor J; Liu CG; Lu Z; El-Deiry WS; Yang JM
    Cancer Biol Ther; 2014 May; 15(5):602-11. PubMed ID: 24557012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
    Auffinger B; Tobias AL; Han Y; Lee G; Guo D; Dey M; Lesniak MS; Ahmed AU
    Cell Death Differ; 2014 Jul; 21(7):1119-31. PubMed ID: 24608791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
    William D; Walther M; Schneider B; Linnebacher M; Classen CF
    PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
    Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
    Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
    [No Abstract]   [Full Text] [Related]  

  • 5. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
    Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
    Ciceroni C; Bonelli M; Mastrantoni E; Niccolini C; Laurenza M; Larocca LM; Pallini R; Traficante A; Spinsanti P; Ricci-Vitiani L; Arcella A; De Maria R; Nicoletti F; Battaglia G; Melchiorri D
    Cell Death Differ; 2013 Mar; 20(3):396-407. PubMed ID: 23175182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
    Joshi K; Banasavadi-Siddegowda Y; Mo X; Kim SH; Mao P; Kig C; Nardini D; Sobol RW; Chow LM; Kornblum HI; Waclaw R; Beullens M; Nakano I
    Stem Cells; 2013 Jun; 31(6):1051-63. PubMed ID: 23404835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
    Zhu TZ; Li XM; Luo LH; Song ZQ; Gao X; Li ZQ; Su JY; Liang GB
    Int J Oncol; 2014 Aug; 45(2):699-709. PubMed ID: 24841897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
    Shi L; Fei X; Wang Z; You Y
    In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1047-55. PubMed ID: 26170223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
    Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
    Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
    Chakraborty S; Li L; Tang H; Xie Y; Puliyappadamba VT; Raisanen J; Burma S; Boothman DA; Cochran B; Wu J; Habib AA
    Neoplasia; 2013 Aug; 15(8):888-97. PubMed ID: 23908590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB.
    Tchoghandjian A; Jennewein C; Eckhardt I; Momma S; Figarella-Branger D; Fulda S
    Cell Death Differ; 2014 May; 21(5):735-47. PubMed ID: 24488095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
    Riganti C; Salaroglio IC; Caldera V; Campia I; Kopecka J; Mellai M; Annovazzi L; Bosia A; Ghigo D; Schiffer D
    Neuro Oncol; 2013 Nov; 15(11):1502-17. PubMed ID: 23897632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
    Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
    J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.